SAN DIEGO, July 28, 2016 /PRNewswire/ -- Sequenom, Inc., (NASDAQ: SQNM), a life sciences company committed to enabling healthier lives through the development of innovative products and services, announced on July 27, 2016 that it entered into a definitive agreement and plan of merger with Laboratory Corporation of America® Holdings (LabCorp®) under which LabCorp would acquire all of the outstanding shares of Seqeunom in a cash tender offer. In light of this announcement, Sequenom has cancelled its second quarter 2016 earnings conference call scheduled to take place on Wednesday, August 3, 2016 at 5:00 p.m. ET (2:00 p.m. PT).
Sequenom, Inc. (NASDAQ: SQNM) is committed to enabling healthier lives through the development of innovative products and services. The Company serves patients and physicians by providing early patient management information. To learn how Sequenom is interpreting the genome to improve your life, please visit www.sequenom.com.
About Sequenom Laboratories
Sequenom Laboratories, a CAP-accredited and CLIA-certified molecular diagnostics laboratory, has developed a broad range of laboratory tests, with a focus principally on prenatal care. Branded under the names HerediT®, MaterniT®, NextView®, SensiGene® and VisibiliT™, these molecular genetic laboratory-developed tests provide early patient management information for obstetricians, geneticists, and maternal fetal medicine specialists. Sequenom Laboratories is changing the landscape in genetic diagnostics using proprietary cutting edge technologies. Please visit www.sequenom.com.
SEQUENOM®, HerediT®, MaterniT®, NextView®, SensiGene®, VisibiliT™ and Sequenom Laboratories™ are trademarks of Sequenom, Inc. All other trademarks and service marks are the property of their respective owners.
SOURCE Sequenom, Inc.